As Enhertu’s reach continues to spread into additional forms of breast cancer, Daiichi Sankyo and AstraZeneca are ramping up ...

ENHERTU, a HER2-directed antibody drug conjugate ... which may be further buoyed by the recent clinical success. Additionally, according to InvestingPro Tips, net income is expected to grow ...

ENHERTU, a HER2-directed antibody drug conjugate ... which may be further buoyed by the recent clinical success. Additionally, according to InvestingPro Tips, net income is expected to grow this year, ...

Public health and health care delivery may seem to go hand in hand to the public they exist to serve. But partnerships for the public good often are complicated by a patchwork of elaborate ...

Shares in AstraZeneca dropped nearly 5 per cent on Tuesday after its failure to hit a target in trials for a next-generation ...

AstraZeneca Plc and Daiichi's breast cancer drug Enhertu is based off of Daiichi's antibody-drug conjugate platform DXd, and ...

Enhertu is already approved for patients with ... could give it an edge over class rival Verzenio from Eli Lilly. The success of clinical trials hinges on a complex array of factors, many of ...

Eltek Ltd. , a global manufacturer and supplier of technologically advanced solutions in the field of printed circuit boards, is pleased to announce the appointment of Tomer Segev as its new Vice ...

Mohit Bansal, an analyst from Wells Fargo, maintained the Hold rating on Jazz Pharmaceuticals (JAZZ – Research Report). The associated ...

In the chemical world, the tiny hyphen in antibody-drug conjugates—or ADCs, as they’re commonly known—does a lot more work ...